Trial Profile
Phase IIa Prospective, Double Blind, Randomized Single-Center, Evaluation of the Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Bronchiolitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nitric oxide (Primary)
- Indications Bronchiolitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors AIT; Beyond Air
- 13 May 2021 Pooled data of patients in the SST group from three studies (AIT-CP-BRONC01-01, AIT-CP-BRONC02-01 and AIT-CP-BRONC-03-01) were published in the Beyond Air media Media Release.
- 15 Jul 2019 According to a Beyond Air media release, the company has changed its name from AIT Therapeutics to Beyond Air.
- 01 Dec 2017 According to an AIT media release, data were publisheded in Pediatric Pulmonology journal.